J. Durant
Publications by Year
Research Areas
HIV/AIDS drug development and treatment, HIV Research and Treatment, HIV/AIDS Research and Interventions, Hepatitis C virus research, HIV-related health complications and treatments
Most-Cited Works
- → Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial(1999)761 cited
- → Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study(2014)325 cited
- → Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study(2012)307 cited
- → Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study(2000)223 cited
- → Persisting Long-Term Benefit of Genotype-Guided Treatment for HIV-Infected Patients Failing Haart. The Viradapt Study: Week 48 Follow-Up(2000)114 cited
- → PharmAdapt(2002)93 cited
- → Immune changes in post-menopausal osteoporosis: the Immunos study(2009)86 cited
- → Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders?(2013)64 cited
- → Reduced incidence of kaposi's sarcoma and of systemic non‐hodgkin's lymphoma in HIV‐infected individuals treated with highly active antiretroviral therapy(2002)61 cited
- → COPD in HIV-Infected Patients: CD4 Cell Count Highly Correlated(2017)50 cited